Latest News Archive

Please select Category, Year, and then Month to display items

Dr Rouxan Fouché’s research helps improve computer literacy in Mangaung

21 April 2023 | Story Rulanzen Martin | Photo Charl Devenish

Dr Rouxan Fouche — Dr Rouxan Fouché on stage in the Callie Human Centre during his graduation ceremony. He hopes his PhD findings will be used to improve the UFS’s Information Technology Service-Learning (ITSL) project’s effectiveness.

When Dr Rouxan Fouché decided to undertake a PhD in Computer Science and Informatics, he was motivated by his commitment to addressing the digital divide in South Africa through service-learning. Through his research, he investigated how the UFS’s Information Technology Service-Learning (ITSL) project could be improved by collaboration with all project stakeholders to positively address and impact the digital divide in the local Mangaung community.

Dr Fouché is a lecturer in the Department of Computer Science and Informatics at the University of the Free State (UFS) and received his PhD during the UFS’s April 2023 graduation ceremonies.

He based his PhD thesis, titled ‘Addressing the South African Digital Divide through a community-informed strategy for Service-Learning: A Critical Utopian Action Research (CUAR) Approach’, on the service-learning module he taught after he realised the positive effect of an information technology-focussed service-learning module on computer literacy levels in the local community. “The initial goal of the service-learning module was to provide free computer literacy training to computer-illiterate community members as part of the students’ community engagement,” Dr Fouché said.

Community-focused PhD research

According to Dr Fouché researchers have recently started looking at how universities can use their service-learning modules (as part of community engagement) to bridge and address the digital divide. He also believes “current conceptualisations indicate that most university service-learning endeavours are organised without engaging with the local community or incorporating their specific needs.”

This is where he hopes his research and findings could make a difference.

His study aimed to re-evaluate and revise the ITSL project by using a hands-on, collaborative approach which included all ITSL project stakeholders. Members of the community served by the project were involved in the shared decision-making and knowledge sharing. “Furthermore, the short-term and lasting impacts of this revised community needs-led ITSL project on the participating community members were investigated.”

The study was conducted in three cycles: Cycle 1 constituted a survey approach to identify the concerns and possible shortcomings of the ITSL project. In Cycle 2, all stakeholders participated in a ‘Future-Creating Workshop’, which reviewed findings from Cycle 1, and a utopian action plan was developed by all involved. Cycle 3 saw the revised project being implemented based on all the recommendations from the previous cycle. “This cycle also included the evaluation of the project’s immediate impact using pre-test and post-test questionnaires completed by project participants.”

Service-learning project made a difference

When Dr Fouché initiated the ITSL project in 2015, the main objective was to serve and equip Mangaung and surrounding communities with necessary computer literacy skills. The programme entails training in Microsoft Word and Excel via two short learning programmes.

The impact of the programme was far-reaching, as it enabled participants to gain formal employment. “The participants told me that they were able to find employment as service station attendants, administrative clerks, and cashiers, among other roles, due to the computer literacy certificates they received after completing the ITSL project.” Witnessing the positive impact of the ITSL programme led Dr Fouché to focus his PhD research on improving the service-learning offerings the UFS provides for the community.

“I realised that it was necessary to investigate how the ITSL project could be improved and tailor-made for the community it serves,” he said.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept